DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Myocardial Ischemia - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Myocardial Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Ischemia and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Myocardial Ischemia Overview
- Therapeutics Development
- Pipeline Products for Myocardial Ischemia - Overview
- Pipeline Products for Myocardial Ischemia - Comparative Analysis
- Myocardial Ischemia - Therapeutics under Development by Companies
- Myocardial Ischemia - Therapeutics under Investigation by Universities/Institutes
- Myocardial Ischemia Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Myocardial Ischemia - Products under Development by Companies
- Myocardial Ischemia - Products under Investigation by Universities/Institutes
- Myocardial Ischemia - Companies Involved in Therapeutics Development
- Baxalta Incorporated
- Bayer AG
- Cellmid Limited
- CohBar, Inc.
- Lixte Biotechnology Holdings, Inc.
- NoNO, Inc.
- Symic Biomedical, Inc.
- Taxus Cardium Pharmaceuticals Group Inc.
- ViroMed Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/7qr88d/myocardial
